Medicilon Logo
search icon search icon language icon contact icon menu icon
Medicilon Logo
search icon close search icon language icon contact icon menu icon
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
Medicilon's News information
News information

Join Medicilon at 2024 North Jersey Drug Metabolism Discussion Group (NJ DMDG) Spring Symposium

Page View:


2024 North Jersey Drug Metabolism Discussion Group (NJ DMDG) Spring Symposium
Discovery, Development, and Regulatory Strategy for Biologics and ADCs in Oncology and Immunology
ADCs are an important class of therapeutics for the treatment of cancer. ADCs are potent cytotoxic agents by linking cytotoxic small molecules to mAbs that directly recognize a specific antigen on tumor cell surface. Compared with the therapeutic mAbs, ADCs-derived monoclonal antibody is conjugated with cytotoxic agents which can deliver potent cellular toxins to targeted cancer cells specifically. To deliver the warhead to the tumour cell, the antibody must bind to the target protein and in general be internalised into the cell. Following internalisation, the cytotoxic agent can be released in the endosomal or lysosomal compartment. Diffusion or transport out of the endosome or lysosome allows the cytotoxic drug to express its cell-killing pharmacology. Alternatively, some ADCs rely on extracellular cleavage releasing membrane permeable warheads.One potentially important aspect of the ADC mechanism is the 'bystander effect' whereby the cytotoxic drug released in the targeted cell can diffuse out of that cell and into other tumour cells to exert its cytotoxic effect.
Over the past couple of decades, ADCs have revolutionized the field of cancer chemotherapy. Unlike conventional treatments that damage healthy tissues upon dose escalation, ADCs utilize mAbs to specifically bind tumor-associated target antigens and deliver a highly potent cytotoxic agent. The synergistic combination of mAbs conjugated to small-molecule chemotherapeutics, via a stable linker, has given rise to an extremely efficacious class of anti-cancer drugs with an already large and rapidly growing clinical pipeline.
The combination of large and small molecule aspects in an ADC poses significant challenges to the disposition scientist in describing the ADME properties of the entire molecule. In this presentation, Dr. Chunlin Chen will review the ADC landscape and the DMPK properties of successful ADCs with Medicilon strategy & experience for dual filing of ADC IND to US FDA & China NMPA, and provide a perspective of how the field can further facilitate the R&D of these important therapeutic modalities.

During the NJ DMDG 2024 Spring Symposium, Dr. Chunlin Chen, Founder&CEO at Medicilon will give this wonderful presentation.
Date: April 11, 2024 (8:00 am - 4:00 pm EST)
Location: The Palace at Somerset Park (333 Davidson Avenue, Somerset, NJ 08873)


Meet with Medicilon
Subject丨2024 NJ DMDG

Relevant newsRelevant news